{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:07:17Z","timestamp":1790982437393,"version":"4.1.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alkermes, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with first-episode psychosis or early-phase schizophrenia are susceptible to olanzapine-associated weight gain and cardiometabolic dysregulation. This meta-analysis characterized weight and metabolic effects observed during olanzapine treatment in randomized clinical trials in this vulnerable patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, EMBASE, and Dialog were searched for randomized controlled trials (RCTs) reporting weight or cardiometabolic outcomes associated with olanzapine treatment in first-episode psychosis or early-phase schizophrenia. Random-effects meta-analysis and meta-regression were conducted using R v4.0.5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1203 records identified, 26 RCTs informed the analyses. The meta-analytic mean (95% CI) weight gain was 7.53 (6.42\u20138.63) kg in studies (n\u2009=\u200919) that reported weight gain with olanzapine treatment. Stratified by duration, the mean (95% CI) weight gain was significantly higher in studies &amp;gt;13 weeks in duration than in those lasting \u226413 weeks: 11.35 (10.05\u201312.65) vs 5.51 (4.73\u20136.28) kg, respectively. Despite between-study variability, increases from baseline in most glycemic and lipid parameters were generally small in studies of both \u226413 and &amp;gt;13 weeks. There were no correlations, however, between weight gain and metabolic parameter changes when stratified by study duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In RCTs enrolling patients with first-episode psychosis or early-phase schizophrenia, olanzapine was consistently associated with weight gain that was greater in studies lasting &amp;gt;13 weeks compared with those of \u226413 weeks. Metabolic changes observed across studies suggest that RCTs may underestimate metabolic sequelae vs real-world treatment observations. Patients with first-episode psychosis or early-phase schizophrenia are vulnerable to olanzapine-associated weight gain; strategies minimizing olanzapine-associated weight gain should be carefully considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyad029","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T21:36:58Z","timestamp":1686865018000},"page":"451-464","source":"Crossref","is-referenced-by-count":28,"title":["Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis"],"prefix":"10.1093","volume":"26","author":[{"given":"Christoph U","family":"Correll","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Zucker Hillside Hospital, Northwell Health , Glen Oaks, New York , USA"},{"name":"Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Hempstead, New York , USA"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"H\u00f8jlund","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark , Odense , Denmark"},{"name":"Department of Psychiatry Aabenraa, Mental Health Services Region of Southern Denmark , Aabenraa , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Graham","sequence":"additional","affiliation":[{"name":"Alkermes, Inc. , Waltham, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Todtenkopf","sequence":"additional","affiliation":[{"name":"Alkermes, Inc. , Waltham, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Alkermes Pharma Ireland Ltd. , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Simmons","sequence":"additional","affiliation":[{"name":"Alkermes, Inc. , Waltham, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"2023073110190341600_CIT0001","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS One"},{"key":"2023073110190341600_CIT0002","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2023073110190341600_CIT0003","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12888-020-02767-x","article-title":"Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey","volume":"20","author":"Bessonova","year":"2020","journal-title":"BMC Psychiatry"},{"key":"2023073110190341600_CIT0004","first-page":"13","article-title":"Statistical methods for analysis of effects of treatment in overviews of randomized trials","volume-title":"Effective care of the newborn infant","author":"Bracken","year":"1992"},{"key":"2023073110190341600_CIT0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"key":"2023073110190341600_CIT0006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.mayocp.2013.11.011","article-title":"A pooled analysis of waist circumference and mortality in 650,000 adults","volume":"89","author":"Cerhan","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2023073110190341600_CIT0007","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/0269881119872193","article-title":"An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes","volume":"33","author":"Cheng","year":"2019","journal-title":"J Psychopharmacol"},{"key":"2023073110190341600_CIT0008","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.pnpbp.2010.04.003","article-title":"The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine","volume":"34","author":"Chiu","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2023073110190341600_CIT0009","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamainternmed.2018.2310","article-title":"Association of obesity or weight change with coronary heart disease among young adults in South Korea","volume":"178","author":"Choi","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2023073110190341600_CIT0010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"key":"2023073110190341600_CIT0011","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/11589060-000000000-00000","article-title":"Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder","volume":"31","author":"Citrome","year":"2011","journal-title":"Clin Drug Investig"},{"key":"2023073110190341600_CIT0012","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"2023073110190341600_CIT0013","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2023073110190341600_CIT0014","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"2023073110190341600_CIT0015","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study","volume":"177","author":"Correll","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2023073110190341600_CIT0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"2023073110190341600_CIT0017","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2023073110190341600_CIT0018","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2023073110190341600_CIT0019","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2147\/PPA.S270020","article-title":"Antipsychotic treatment experiences of people with schizophrenia: patient perspectives from an online survey","volume":"14","author":"Doane","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2023073110190341600_CIT0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"2023073110190341600_CIT0021","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2023073110190341600_CIT0022","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2023073110190341600_CIT0023","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2023073110190341600_CIT0024","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2006.06.021","article-title":"Olanzapine and haloperidol in first episode psychosis: two-year data","volume":"86","author":"Green","year":"2006","journal-title":"Schizophr Res"},{"key":"2023073110190341600_CIT0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pnpbp.2017.10.021","article-title":"A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients","volume":"81","author":"Huang","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2023073110190341600_CIT0026","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"2023073110190341600_CIT0027","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"2023073110190341600_CIT0028","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2023073110190341600_CIT0029","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry"},{"key":"2023073110190341600_CIT0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/eurheartj\/ehz388","article-title":"Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study","volume":"41","author":"Larsson","year":"2020","journal-title":"Eur Heart J"},{"key":"2023073110190341600_CIT0031","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4088\/JCP.v69n0107","article-title":"A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia","volume":"69","author":"Law","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2023073110190341600_CIT0032","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"2023073110190341600_CIT0033","first-page":"177","article-title":"Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study","volume":"45","author":"Li","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"2023073110190341600_CIT0034","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"2023073110190341600_CIT0035","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol","volume":"160","author":"Lieberman","year":"2003","journal-title":"Am J Psychiatry"},{"key":"2023073110190341600_CIT0036","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"2023073110190341600_CIT0037","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1586\/ern.10.85","article-title":"Management of antipsychotic-related weight gain","volume":"10","author":"Maayan","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"2023073110190341600_CIT0038","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2023073110190341600_CIT0039","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr Res"},{"key":"2023073110190341600_CIT0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1093","article-title":"Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine","volume":"14","author":"Moisan","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023073110190341600_CIT0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"2023073110190341600_CIT0042","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00213-012-2850-6","article-title":"Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia","volume":"225","author":"Ou","year":"2013","journal-title":"Psychopharmacology"},{"key":"2023073110190341600_CIT0043","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr Res"},{"key":"2023073110190341600_CIT0044","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","article-title":"A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone","volume":"68","author":"Perez-Iglesias","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"2023073110190341600_CIT0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophr Res"},{"key":"2023073110190341600_CIT0046","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2008.09.028","article-title":"Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population","volume":"107","author":"Perez-Iglesias","year":"2009","journal-title":"Schizophr Res"},{"key":"2023073110190341600_CIT0047","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2023073110190341600_CIT0048","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1176\/appi.ajp.159.6.1058","article-title":"Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition","volume":"159","author":"Poyurovsky","year":"2002","journal-title":"Am J Psychiatry"},{"key":"2023073110190341600_CIT0049","author":"R Foundation","year":"2002"},{"key":"2023073110190341600_CIT0050","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fnins.2017.00741","article-title":"The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment","volume":"11","author":"Raben","year":"2018","journal-title":"Front Neurosci"},{"key":"2023073110190341600_CIT0051","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/jcp.0b013e3181602fe6","article-title":"Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol","volume":"28","author":"Saddichha","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"2023073110190341600_CIT0052","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0447.2008.01158.x","article-title":"Diabetes and schizophrenia\u2014effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia","volume":"117","author":"Saddichha","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"2023073110190341600_CIT0053","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2008.01.004","article-title":"Metabolic syndrome in first episode schizophrenia\u2014a randomized double-blind controlled, short-term prospective study","volume":"101","author":"Saddichha","year":"2008","journal-title":"Schizophr Res"},{"key":"2023073110190341600_CIT0054","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.psychres.2012.07.005","article-title":"One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis","volume":"200","author":"San","year":"2012","journal-title":"Psychiatry Res"},{"key":"2023073110190341600_CIT0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/ajp.156.1.79","article-title":"Olanzapine versus haloperidol treatment in first-episode psychosis","volume":"156","author":"Sanger","year":"1999","journal-title":"Am J Psychiatry"},{"key":"2023073110190341600_CIT0056","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"2023073110190341600_CIT0057","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"2023073110190341600_CIT0058","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2023073110190341600_CIT0059","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41386-021-01244-7","article-title":"Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers","volume":"47","author":"Toledo","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"2023073110190341600_CIT0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"key":"2023073110190341600_CIT0061","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00213-006-0384-5","article-title":"Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"186","author":"Wu","year":"2006","journal-title":"Psychopharmacology"},{"key":"2023073110190341600_CIT0062","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/JCP.0b013e3180cac8db","article-title":"Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"27","author":"Wu","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"2023073110190341600_CIT0063","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S0033291714001305","article-title":"A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania","volume":"45","author":"Yildiz","year":"2015","journal-title":"Psychol Med"},{"key":"2023073110190341600_CIT0064","first-page":"339","article-title":"Prospective 8-week trial on the effect of olanzapine, quetiapine, and aripiprazole on blood glucose and lipids among individuals with first-onset schizophrenia","volume":"26","author":"Zhang","year":"2014","journal-title":"Shanghai Arch Psychiatry"},{"key":"2023073110190341600_CIT0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jama.2017.7092","article-title":"Associations of weight gain from early to middle adulthood with major health outcomes later in life","volume":"318","author":"Zheng","year":"2017","journal-title":"JAMA"},{"key":"2023073110190341600_CIT0066","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses","volume":"4","author":"Zhu","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"2023073110190341600_CIT0067","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1192\/bjp.187.6.537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol","volume":"187","author":"Zipursky","year":"2005","journal-title":"Br J Psychiatry"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyad029\/50842601\/pyad029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/7\/451\/51010278\/pyad029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/7\/451\/51010278\/pyad029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T06:21:09Z","timestamp":1690784469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/26\/7\/451\/7199539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":67,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,16]]},"published-print":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyad029","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,6,16]]}}}